Sponsored By
THE WINNERS HAVE BEEN ANNOUNCED!
Join us for the 10th anniversary of the Global Generics and Biosimilars Awards celebrating the greatest achievements and innovations across the development, authorization, marketing and distribution of global off-patent pharmaceuticals.
Co-locating with CPhI Worldwide in Barcelona, these illustrious awards provide a unique opportunity for the industry to come together to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change. Winners will be recognized across 14 categories, including Biosimilar Initiative of the Year, Leader of the Year, API Supplier of the Year and new for 2023, Campaign of the Year.
The Global Generics and Biosimilars Awards are free to enter. The judging process will take place over the summer. The finalists will be announced in September and the winners revealed at the Awards on 25 October 2023.
Key details
Ceremony: Wednesday, 25 October, 2023
Hotel Porta Fira, Barcelona
2023 Photo Gallery
WHO COULD ENTER
Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.
WINNER
- Biocon Biologics - acquisition of Viatris biosimilars business
FINALISTS
- Adalvo - acquisition of Onsolis
- Biocon Biologics - acquisition of Viatris biosimilars business
- Rising Pharmaceuticals - acquisition of Akorn assets
- Sandoz - acquisition of Mycamine from Astellas
- Zentiva - acquisition of Sanofi Consumer Health brands
WHO COULD ENTER
Open to any company supplying off-patent active pharmaceutical ingredients (APIs) or intermediates.
WINNER
- Olon Group
FINALISTS
- MSN Laboratories
- Neuland Laboratories
- Olon Group
- Piramal Pharma Solutions
- R L Fine Chem
- Solara Active Pharma Sciences
.png?la=en&h=56&w=100&hash=760324F6A7B800C95ADBF913FE9EDBC0){kind=logo}
WHO COULD ENTER
Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.
WINNER
- Polpharma Biologics
FINALISTS
- Accord Healthcare
- Celltrion Healthcare
- Lambda Therapeutic Research
- Polpharma Biologics
- Samsung Bioepis
- Sandoz
- Similis Bio
WHO COULD ENTER
Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.
WINNER
- Sandoz
FINALISTS
- Accord Healthcare
- Adalvo
- Aurobindo Pharma
- Biocon
- Sandoz
- Similis Bio
- Zentiva
WHO COULD ENTER
This category allows industry firms and organizations to highlight outstanding campaigns used to successfully promote and highlight generics, biosimilars and value-added medicines across the world. This could include awareness campaigns, efforts to highlight key industry contributions to a wider audience, or initiatives that raise the profile of off-patent medicines for healthcare industry stakeholders.
WINNER
- Biosimilars Canada - #MakeTheSwitch
FINALISTS
- Association for Accessible Medicines - #4GRxANTED
- Biosimilars Canada - #MakeTheSwitch
- Canadian Generic Pharmaceutical Association - #PrescriptionForCanada
- Celltrion Healthcare - the "Where’s CC (Crohn’s & Colitis)?" Campaign
- International Generic and Biosimilar Medicines Association - Global Biosimilars Week Campaign
- Samsung Bioepis - “Why Biosimilars” Campaign
- Sandoz - Act4Biosimilars Action Plan
WHO COULD ENTER
Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.
WINNER
- Sandoz
FINALISTS
- Accord Healthcare
- Biocon Biologics
- Celltrion Healthcare
- Samsung Bioepis
- Sandoz
- STADA
WHO COULD ENTER
Open to any company that generates at least a third, or at least US$250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business.
WINNER: Company of the Year – Americas
- Dr.Reddy's Americas
FINALISTS: Company of the Year – Americas
- Amneal Pharmaceuticals
- Coherus BioSciences
- Dr.Reddy's Americas
WINNER: Company of the Year – Asia-Pacific
- Samsung Bioepis
FINALISTS: Company of the Year – Asia-Pacific
- Aurobindo Pharma
- Beximco Pharma
- Biocon Biologics
- Samsung Bioepis
- Shanghai Henlius Biotech
- Surge Laboratories
WINNER: Company of the Year – EMEA
- Accord Healthcare
FINALISTS: Company of the Year – EMEA
- Accord Healthcare
- Sandoz
- STADA
WHO COULD ENTER
Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, raining & education programmes, compulsory licensing and humanitarian aid donations.
WINNER
- Teva Pharmaceuticals
FINALISTS
- Accord Healthcare
- Centrient Pharmaceuticals
- Dr. Reddy's Laboratories
- Eurofarma Laboratórios
- Shanghai Henlius Biotech
- Teva Pharmaceuticals
WHO COULD ENTER
Awarded to recognize outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract-manufacturers, law firms and consultants.
WINNER
- Lambda Therapeutic Research
FINALISTS
- Adalvo
- Affygility Solutions
- Biocon
- Centrient Pharmaceuticals and Ginkgo Bioworks
- Inoviem Scientific
- Lambda Therapeutic Research
- Surge Laboratories
WHO COULD ENTER
Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.
WINNER
- Richard Saynor, Sandoz
FINALISTS
- Anil Okay, Adalvo
- Apurva Saraf, Cosette Pharmaceuticals
- Paul Tredwell,Accord Healthcare EMENA
- Peter Goldschmidt, STADA
- Rachel Goode, Fresenius Kabi
- Richard Saynor, Sandoz
WHO COULD ENTER
Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.
WINNER
- Samsung Bioepis
FINALISTS
- Adalvo
- Ami Lifesciences
- Aurobindo Pharma
- Dr. Reddy's Laboratories
- Samsung Bioepis
- Zentiva
WHO COULD ENTER
Entries in this category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.
WINNER
- Sun Pharma
FINALISTS
- Accord Biopharma
- Adalvo
- Cadila Pharmaceuticals
- PharmEvo
- Sun Pharma
- Zentiva – Dasatinib
- Zentiva - Omeprazole
HEADLINE SPONSOR
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com.
The company that started less than four decades ago as a single unit manufacturing Semi-Synthetic Penicillin (SSP) has now grown into a $ 3.5 billion global business with presence in over 150 countries and in all major therapeutic segments; API, FDF, Biocatalysts , Vaccines, Peptides and Biologicals.
With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs in India.
exclusively for the generics, biosimilars and specialty pharmaceutical
industries in Europe, North America and Asia. From our
offices in London, Belgium and the US we operate in over 60 countries connecting
our clients with the best available leaders. Our team works relentlessly to
leverage their extensive networks to ensure our clients always make the right
hire at the right time. Our team can each leverage over 10 years minimum in the
executive search industry using comprehensive and robust research capabilities
allied with modern CRM tools. We have an unrivalled candidate network to draw
upon, meaning we have a market-leading response rate from candidates on each
search. For more information visit www.parsitygroup.com
The research side of our business is currently being built up, starting from the base of our well-regarded industry blog. Look out for the first in our series of in-depth reports beginning in 2015.
- due-diligence, acquisition screening and post-deal support
- portfolio optimization and pipeline design or selection
- mature brand strategy and life cycle management
- product or portfolio in-licensing and out-licensing
- quality, pharmacovigilance and regulatory audits
- operational and supply chain optimization
- product and process development
- organizational design and culture
- intellectual property and patents
- strategy development
We match deep know-how and know-who to your generic or biosimilar needs: our project teams include highly knowledgeable experts with ~20 years executive experience and networks at successful global or local generic companies and leading management consulting firms in the above-mentioned areas.
If your responsibilities match our expertise, we would love to hear from you. Contact us at www.pharma-wise.com
2023 marks West’s 100-year milestone of innovation and the critical role it continues to play in healthcare and the patient experience. Headquartered in Exton, Pennsylvania, West in its fiscal year 2022 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.
The Biosimilars Council is a division of the Association for Accessible Medicines, an organization dedicated to improving access to safe, quality, effective medicine. To learn more, visit www.accessiblemeds.org
We provide cutting-edge lead generation and brand programmes to help you reach and collaborate with audiences across industry events and digital platforms.
